On 20 May 2022 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation:
Recommendation No. 44/2022 of 20 May 2022 of the President of the Agency for Health Technology Assessment and Tariff System on the inclusion in the reimbursement procedure of the medicinal product: Tysabri, natalizumab, solution for injection, 150 mg, 2, ampoule syringe containing 1 ml of solution, GTIN 05713219560252, for the indication under the new drug programme “Treatment of multiple sclerosis (ICD-10 G35) with natalizumab administered subcutaneously”.